Physician
Hematology
Dr. Kyriakos P. Papadopoulos, MD
|
|
Give Review
Kyriakos Papadopoulos is an expert in the field of Hematology. He over the years received 1 awards: "Top Doctors:SE Texas". Kyriakos Papadopoulos is also published. He has 65 publications published. The lastest publication: "High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS tumors in children and adults.' Kyriakos P. Papadopoulos is registered with Medicare.
Publications
- A first-in-human dose-escalation study of the oral proteasome inhibitor oprozomib in patients with advanced solid Tumors.
- A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer.
- A phase I first-in-human study of Nesvacumab (REGN910), a fully-human anti-Angiopoietin-2 (Ang2) monoclonal antibody, in patients with advanced solid Tumors.
- Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody(®) targeting the DR5 receptor.
- A phase IB trial of the oral MEK inhibitor trametinib (GSK1120212) in combination with everolimus in patients with advanced solid Tumors.
- Interrogating Two Schedules of the AKT Inhibitor MK-2206 in Patients with Advanced Solid Tumors Incorporating Novel Pharmacodynamic and Functional Imaging Biomarkers.
- Efficacy, safety, pharmacokinetics and pharmacodynamics of SAR245409 (voxtalisib, XL765), an Orally administered phosphoinositide 3-kinase/mammalian target of rapamyci...
- Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple Myeloma.
- Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple M...
- Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple Myeloma.
- Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in Cancer patients: Model prediction and clinical confirmation.
- A phase I study of the human monoclonal anti-NRP1 antibody MNRP1685A in patients with advanced solid Tumors.
- A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 monoclonal antibody, in combination with bevacizumab and paclitaxel in patients with advanced solid Tumors.
- A phase I trial of LY2584702 tosylate, a p70 S6 kinase inhibitor, in patients with advanced solid tumours.
- Phase I safety, pharmacokinetic and pharmacodynamic study of SAR245409 (XL765), a novel, orally administered PI3K/mTOR inhibitor in patients with advanced solid Tumors.
- A phase 1 study of the BCL2-targeted deoxyribonucleic acid inhibitor (DNAi) PNT2258 in patients with advanced solid Tumors.
- A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid Tumors.
- A phase 1b study of trametinib, an Oral Mitogen-activated protein kinase kinase (MEK) inhibitor, in combination with gemcitabine in advanced solid tumours.
- Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced Cancer.
- A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid Tumors.
- Clinical pharmacokinetics, metabolism, and drug-drug interaction of carfilzomib.
- Phase I Study of RO4929097, a Gamma Secretase Inhibitor of Notch Signaling, in Patients With Refractory Metastatic or Locally Advanced Solid Tumors.
- The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTOR and RAS/MEK/ERK pathways in patients with advanced Cancer.
- First-in-man clinical trial of the oral pan-AKT inhibitor MK-2206 in patients with advanced solid Tumors.
- Erlotinib ''dosing-to-rash'': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung Cancer.
- Phase I and pharmacokinetic study of CT-322 (BMS-844203), a targeted Adnectin inhibitor of VEGFR-2 based on a domain of human fibronectin.
- Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid Tumors or lymphomas.
- Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1.
- Satraplatin, an Oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
- Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid Tumors.
- Development of PARP inhibitors in oncology.
- Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid Tumors.
- Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.
- A phase 1 open-label, accelerated dose-escalation study of the hypoxia-activated prodrug AQ4N in patients with advanced Malignancies.
- Future options for imatinib mesilate-resistant Tumors.
- Novel targeted therapies for advanced esophageal Cancer.
- Screening for hepatoCellular carcinoma among veterans with hepatitis C on disease stage, treatment received, and survival.
- Targeting the Bcl-2 family in Cancer therapy.
- Cost utility of substituting enoxaparin for unfractionated heparin for prophylaxis of venous thrombosis in the hospitalized medical patient.
- Pilot study of tandem high-dose chemotherapy and autologous stem Cell transplantation with a novel combination of regimens in patients with poor risk lymphoma.
- Current chemotherapy options for thymic epithelial neoplasms.
- Synergistic effects of acyclic retinoid and OSI-461 on growth inhibition and gene expression in human hepatoma Cells.
- Renal medullary Carcinoma: case report and review of the literature.
- Gene expression profiling and functional activity of human dendritic cells induced with IFN-alpha-2b: implications for Cancer immunotherapy.
- Multiepitope CD8(+) T Cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.
- Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support ...
- Mild or moderate chronic obstructive pulmonary disease risk in elective coronary artery bypass grafting surgery.
- Tandem transplantation in Lymphoma.
- Transcript profiling of human dendritic Cells maturation-induced under defined culture conditions: comparison of the effects of tumour necrosis factor alpha, soluble C...
- Reduction of paclitaxel-induced peripheral neuropathy with glutamine.
- The pharmacokinetics and pharmacodynamics of high-dose paclitaxel monotherapy (825 mg/m2 continuous infusion over 24 h) with hematopoietic support in women with metast...
- A novel closed System utilizing styrene copolymer bead adherence for the production of human dendritic cells.
- Bilateral facial nerve palsy Secondary to the administration of high-dose paclitaxel.
- A phase I study of high-dose BCNU, etoposide and escalating-dose thiotepa (BTE) with hematopoietic progenitor cell support in adults with recurrent and high-risk Brain...
- CD34+ Cell dose requirements for rapid engraftment in a sequential high-dose chemotherapy regimen of paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carbopl...
- Wild-type p53 epitope naturally processed and presented by an HLA-B haplotype on human Breast carcinoma cells.
- Translocation (4;15)(p16;q24): a novel reciprocal translocation in a patient with BCR/ABL negative myeloproliferative syndrome progressing to blastic phase.
- High-dose thiotepa and etoposide-based regimens with autologous hematopoietic support for high-risk or recurrent CNS Tumors in children and adults.
- Phase I trial of sequential high-dose chemotherapy with escalating dose paclitaxel, melphalan, and cyclophosphamide, thiotepa, and carboplatin with peripheral blood pr...
- Naturally processed Tissue- and differentiation stage-specific autologous peptides bound by HLA class I and II molecules of chronic myeloid leukemia blasts.
- TempOral variation in chlorinated hydrocarbons in healthy women.
- MHC class I antigen processing pathways.
- Harvest quality and factors affecting collection and engraftment of CD34+ cells in patients with breast Cancer scheduled for high-dose chemotherapy and peripheral bloo...
- Tissue-specific self-peptides bound by major histocompatibility complex class I molecules of a human pancreatic beta-Cell line.
Conditions Treated
- Anal and Rectal Cancer
- Anemia
- Bladder Cancer
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Hematology
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Top Doctors:SE Texas
Education
-
New York Presbyterian Hospital -
New York Presbyterian Hospital - Columbia Campus -
University of the Witwatersrand
Drug Facts
| NPI NUMBER | 1376546861 | |
| NPPES Provider LastName | PAPADOPOULOS | |
| NPPES Provider FirstName | KYRIAKOS | |
| NPPES Provider ZIPCode | 782293307 | |
| NPPES Provider State | TX | |
| Specialty Description | Medical Oncology | |
| Total Claim Count | 324.0 | |
| Distinct Opioid Count | 2.0 | |
| Opioid Claim Count | 56.0 | |
| Percent Opioid Claims | 17.28 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1376546861 |
| Last Name Of The Provider | PAPADOPOULOS |
| First Name Of The Provider | KYRIAKOS |
| View All |
Similar Doctors
|
|
Dr. Francisco C. Rodriguez, MD |
|
|
Dr. Drew W. Rasco, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sharon T. Wilks, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Amy S. Lang, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sridhar Beeram, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lon S. Smith, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edsel L. Hesita, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Manuel A. Santiago, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew J. Brenner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Cesar Freytes, MD
This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
|
Dr. Sushma Vemulapalli, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Edward A. Medina, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael A. Wiggins, MD |